HACKENSACK, N.J., April 4, 2013 (GLOBE NEWSWIRE) -- Champions Oncology, Inc. (OTC:CSBR) is pleased to announce that it will be presenting six posters on its Champions TumorGraft™ models and Translational Oncology Solutions at the 2013 American Association of Cancer Research (AACR) Annual Meeting being held April 6 - 10 in Washington, DC. Champions will also be exhibiting at the event at Booth #1008.
The posters represent Champions' investment in research and development to expand the value of TumorGraft technology for drug development. The work to be presented will include advancements in targeted TumorGraft model development, characterization of relevant cancer pathways, as well as collaborative work on cancer cachexia models and the utility of next generation DNA sequencing in personalized cancer treatment.
Joel Ackerman, Champions Oncology's CEO, stated, "We are very excited to be presenting several key advancements in our TumorGraft technology platform at the 2013 AACR Annual Meeting. We also look forward to discussing the application of these advancements with the cancer research community during the event."The posters can be viewed during the following times during the AACR Annual Meeting. For questions, reprints of the posters, or to arrange a meeting with Champions staff during the event, please contact us here.
|Poster Title||Abstract #||Date||Time||Section #||Board #|
|Integrated next generation sequencing and patient-derived xenografts to personalized cancer treatment||2205||Monday, April 8, 2013||1:00 PM-5:00 PM||42||14|
|Development of an androgen-dependent prostate Champions TumorGraft™ cancer model||2783||Tuesday, April 9, 2013||8:00 AM - 12:00 PM||19||21|
|Characterization of spontaneous in vivo cachexia models in Champions TumorGraft™ models||2792||Tuesday, April 9, 2013||8:00 AM - 12:00 PM||19||20|
|Champions TumorGraft™ models represent oncology clinical trial populations||2779||Tuesday, April 9, 2013||8:00 AM - 12:00 PM||19||26|
|Champions TumorGraft™ models possess PIK3CA mutations - A great tool to explore the PI3K/AKT pathway||2774||Tuesday, April 9, 2013||8:00 AM - 12:00 PM||19||9|
|Functional profiling of Champions TumorGraft™ models from metastatic melanoma patients||3498||Tuesday, April 9, 2013||1:00 PM - 5:00 PM||2||16|
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts